AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors	2214	147511-69-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nisvastatin itavastatin pitavastatin calcium hydrate pitavastatin pitavastatin calcium livalo	Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of cholesterol, in a manner of competition with the substrate so that it inhibits cholesterol synthesis in the liver. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition of cholesterol synthesis in the liver decreases levels of very low density lipoproteins. Molecular weight: 421.47 Formula: C25H24FNO4 CLOGP: 3.59 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 90.65 ALOGS: -5.03 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nisvastatin
itavastatin
pitavastatin calcium hydrate
pitavastatin
pitavastatin calcium
livalo

Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of cholesterol, in a manner of competition with the substrate so that it inhibits cholesterol synthesis in the liver. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition of cholesterol synthesis in the liver decreases levels of very low density lipoproteins.

Molecular weight: 421.47
Formula: C25H24FNO4
CLOGP: 3.59
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 90.65
ALOGS: -5.03
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.90 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.85 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.60 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	51 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability)	0.80 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC,TGFBR1	9
kinase-selectivity-class	ACVR2B,AXL	2
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	14.622		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		High	1
rat-kpuu-brain	Rat brain Kpuu	0.011	%	High	1

Approvals:

Date	Agency	Company	Orphan
Aug. 3, 2009	FDA	KOWA CO
June 26, 2015	PMDA	Kowa Company, Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	247.54	16.75	168	7947	174957	90445375
Hepatic function abnormal	121.06	16.75	66	8049	46222	90574110
Cerebral infarction	110.88	16.75	52	8063	26544	90593788
Rhabdomyolysis	74.13	16.75	50	8065	51206	90569126
Blood creatine phosphokinase increased	68.72	16.75	41	8074	33982	90586350
Renal impairment	58.72	16.75	59	8056	105362	90514970
Haemorrhage subcutaneous	47.73	16.75	16	8099	3380	90616952
Interstitial lung disease	46.70	16.75	45	8070	76360	90543972
Anaemia	39.24	16.75	93	8022	352709	90267623
Altered state of consciousness	39.10	16.75	28	8087	31504	90588828
Platelet count decreased	38.42	16.75	54	8061	136915	90483417
Drug eruption	34.04	16.75	27	8088	35380	90584952
Enterocolitis	33.19	16.75	17	8098	10473	90609859
Pemphigoid	32.59	16.75	16	8099	9010	90611322
Lymphocyte stimulation test positive	28.54	16.75	7	8108	484	90619848
Hypoglycaemia	28.19	16.75	33	8082	69815	90550517
Aspartate aminotransferase increased	27.99	16.75	40	8075	102897	90517435
Alanine aminotransferase increased	27.89	16.75	43	8072	118295	90502037
Akinesia	27.69	16.75	9	8106	1727	90618605
Vulvovaginal inflammation	27.29	16.75	8	8107	1090	90619242
Liver disorder	27.10	16.75	43	8072	121226	90499106
Muscle spasms	26.47	16.75	65	8050	251818	90368514
Cardiac failure	26.10	16.75	40	8075	109456	90510876
Toxic encephalopathy	24.38	16.75	13	8102	8686	90611646
Decreased appetite	23.85	16.75	81	8034	376459	90243873
Erythema multiforme	22.76	16.75	14	8101	12232	90608100
Glucose-6-phosphate dehydrogenase deficiency	22.36	16.75	5	8110	231	90620101
Systemic lupus erythematosus	22.32	16.75	3	8112	361893	90258439
Gingival oedema	20.54	16.75	4	8111	93	90620239
Cerebral haemorrhage	20.45	16.75	20	8095	34502	90585830
Upper respiratory tract inflammation	20.32	16.75	8	8107	2664	90617668
Hyperkalaemia	20.29	16.75	27	8088	64937	90555395
Pneumonia bacterial	19.74	16.75	13	8102	12777	90607555
Pancreatic carcinoma	19.30	16.75	11	8104	8366	90611966
Myopathy	19.08	16.75	13	8102	13505	90606827
Myocardial infarction	18.92	16.75	34	8081	105938	90514394
Dyspnoea at rest	18.83	16.75	9	8106	4782	90615550
Gastric dysplasia	18.49	16.75	3	8112	23	90620309
Vessel puncture site haematoma	18.45	16.75	4	8111	160	90620172
Arthropathy	18.44	16.75	5	8110	366237	90254095
Cardiac failure acute	18.10	16.75	12	8103	11917	90608415
Chronic kidney disease	17.46	16.75	22	8093	50169	90570163
Embolic stroke	17.08	16.75	8	8107	4064	90616268
Blood urea increased	16.87	16.75	17	8098	30396	90589936

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	136.03	15.74	118	8435	78344	42534438
Hepatic function abnormal	133.12	15.74	98	8455	51469	42561313
Myalgia	130.48	15.74	126	8427	95954	42516828
Cerebral infarction	110.43	15.74	72	8481	31097	42581685
Blood creatine phosphokinase increased	90.41	15.74	76	8477	48262	42564520
Rhabdomyolysis	49.17	15.74	69	8484	77950	42534832
Cardiac failure	45.66	15.74	79	8474	106777	42506005
Angina pectoris	42.39	15.74	42	8511	32854	42579928
Immune-mediated myositis	39.72	15.74	18	8535	3775	42609007
Liver disorder	35.90	15.74	42	8511	39602	42573180
Aspartate aminotransferase increased	32.87	15.74	57	8496	77106	42535676
Pemphigoid	32.27	15.74	23	8530	11444	42601338
Renal impairment	30.61	15.74	68	8485	110160	42502622
Hyperuricaemia	29.08	15.74	20	8533	9404	42603378
Subdural haematoma	28.80	15.74	29	8524	23109	42589673
Visceral pain	28.53	15.74	6	8547	89	42612693
Death	27.04	15.74	33	8520	471152	42141630
Decreased appetite	23.89	15.74	89	8464	193048	42419734
Glycosylated haemoglobin increased	23.47	15.74	20	8533	12904	42599878
Drug-induced liver injury	22.83	15.74	33	8520	38240	42574542
Urine ketone body present	22.52	15.74	9	8544	1385	42611397
Prostate cancer	21.69	15.74	35	8518	44608	42568174
Pneumonia aspiration	21.32	15.74	37	8516	50041	42562741
Alanine aminotransferase increased	20.66	15.74	51	8502	88355	42524427
Pulmonary sepsis	20.50	15.74	11	8542	3313	42609469
Drug eruption	20.14	15.74	24	8529	23051	42589731
Gastric cancer	19.78	15.74	14	8539	6889	42605893
Colon cancer	19.69	15.74	16	8537	9665	42603117
Embolic cerebral infarction	18.87	15.74	7	8546	882	42611900
Cardiac failure acute	18.66	15.74	18	8535	13615	42599167
Bronchitis chronic	18.34	15.74	8	8545	1533	42611249
Anaemia	17.57	15.74	106	8447	280172	42332610
Gamma-glutamyltransferase	17.52	15.74	3	8550	13	42612769
Myopathy	16.67	15.74	17	8536	13744	42599038
Diabetes mellitus	16.58	15.74	37	8516	60050	42552732
Pyelonephritis	15.93	15.74	13	8540	7901	42604881
Diverticulum intestinal haemorrhagic	15.90	15.74	9	8544	3010	42609772

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	315.08	14.24	263	16321	222118	110350597
Hepatic function abnormal	248.45	14.24	159	16425	89136	110483579
Cerebral infarction	208.37	14.24	117	16467	51721	110520994
Interstitial lung disease	177.05	14.24	155	16429	139179	110433536
Blood creatine phosphokinase increased	141.25	14.24	104	16480	72973	110499742
Rhabdomyolysis	110.73	14.24	112	16472	120289	110452426
Renal impairment	80.60	14.24	119	16465	188326	110384389
Altered state of consciousness	68.90	14.24	62	16522	57564	110515151
Pemphigoid	64.61	14.24	39	16545	19668	110553047
Cardiac failure	62.92	14.24	106	16478	187520	110385195
Aspartate aminotransferase increased	55.81	14.24	92	16492	159844	110412871
Decreased appetite	55.49	14.24	177	16407	475669	110097046
Immune-mediated myositis	51.79	14.24	23	16561	6163	110566552
Anaemia	51.11	14.24	189	16395	546897	110025818
Amaurosis fugax	48.98	14.24	17	16567	2373	110570342
Angina pectoris	48.40	14.24	53	16531	62242	110510473
Drug eruption	45.82	14.24	48	16536	53611	110519104
Platelet count decreased	45.29	14.24	104	16480	230339	110342376
Alanine aminotransferase increased	44.19	14.24	90	16494	183683	110389032
Liver disorder	43.27	14.24	77	16507	142166	110430549
Hyperuricaemia	40.66	14.24	26	16558	14505	110558210
Drug ineffective	38.26	14.24	110	16474	1520430	109052285
Haemorrhage subcutaneous	38.21	14.24	18	16566	5521	110567194
Enterocolitis	34.42	14.24	26	16558	18923	110553792
Myopathy	34.14	14.24	29	16555	24931	110547784
Subdural haematoma	33.63	14.24	34	16550	36420	110536295
Glycosylated haemoglobin increased	33.45	14.24	28	16556	23591	110549124
Cardiac failure acute	32.98	14.24	28	16556	24050	110548665
Confusional state	32.21	14.24	15	16569	468665	110104050
Hypoglycaemia	31.70	14.24	60	16524	116044	110456671
Pneumonia bacterial	30.88	14.24	28	16556	26233	110546482
Ocular discomfort	30.88	14.24	18	16566	8515	110564200
Colon cancer	30.84	14.24	23	16561	16420	110556295
Pneumonia aspiration	30.04	14.24	48	16536	81185	110491530
Upper respiratory tract inflammation	29.52	14.24	14	16570	4357	110568358
Prostate cancer	29.19	14.24	32	16552	37609	110535106
Urinary tract disorder	28.48	14.24	15	16569	5829	110566886
Treatment failure	28.25	14.24	4	16580	277230	110295485
Visceral pain	27.79	14.24	6	16578	138	110572577
Lymphocyte stimulation test positive	27.52	14.24	9	16575	1047	110571668
Arthropathy	27.39	14.24	5	16579	287517	110285198
Diabetes mellitus	26.69	14.24	51	16533	99330	110473385
Gastric cancer	26.66	14.24	18	16566	10990	110561725
Haematuria	26.61	14.24	46	16538	82959	110489756
Akinesia	25.55	14.24	12	16572	3655	110569060
Embolic stroke	25.35	14.24	16	16568	8727	110563988
Haemorrhagic stroke	25.22	14.24	19	16565	13770	110558945
Systemic lupus erythematosus	25.16	14.24	4	16580	254334	110318381
Acute myocardial infarction	25.01	14.24	45	16539	83732	110488983
Urine ketone body present	25.00	14.24	12	16572	3834	110568881
Blood lactate dehydrogenase increased	24.95	14.24	32	16552	44302	110528413
Femoral neck fracture	24.51	14.24	18	16566	12549	110560166
Embolic cerebral infarction	24.40	14.24	9	16575	1497	110571218
Toxicity to various agents	24.04	14.24	22	16562	480533	110092182
Pancreatic carcinoma	23.94	14.24	19	16565	14853	110557862
Erythema multiforme	23.84	14.24	22	16562	21075	110551640
Therapeutic product effect decreased	23.81	14.24	4	16580	244312	110328403
Joint swelling	23.70	14.24	19	16565	442826	110129889
Lower respiratory tract infection	23.65	14.24	4	16580	243102	110329613
Completed suicide	23.55	14.24	4	16580	242377	110330338
Hypersensitivity	23.34	14.24	16	16568	403982	110168733
Pyelonephritis	22.29	14.24	23	16561	25227	110547488
Cerebral haemorrhage	22.14	14.24	37	16547	64931	110507784
Hyperkalaemia	22.07	14.24	57	16527	135739	110436976
General physical health deterioration	21.83	14.24	19	16565	425276	110147439
Swelling	21.51	14.24	13	16571	351028	110221687
Immobilisation syndrome	20.96	14.24	7	16577	869	110571846
Dyslipidaemia	20.71	14.24	18	16566	15947	110556768
Blood pressure decreased	20.48	14.24	50	16534	115041	110457674
Anorgasmia	20.08	14.24	8	16576	1638	110571077
Diabetic ketoacidosis	20.06	14.24	28	16556	42030	110530685
Neutrophil count decreased	19.90	14.24	51	16533	120890	110451825
Diverticulum intestinal haemorrhagic	19.80	14.24	11	16573	4752	110567963
Blood triglycerides increased	19.70	14.24	21	16563	23905	110548810
Hyperglycaemia	19.64	14.24	41	16543	85049	110487666
Wheezing	19.41	14.24	7	16577	255223	110317492
Alopecia	19.08	14.24	16	16568	364737	110207978
Pulmonary sepsis	18.74	14.24	11	16573	5267	110567448
Spinal compression fracture	18.53	14.24	18	16566	18374	110554341
Off label use	18.31	14.24	141	16443	1500044	109072671
Vulvovaginal inflammation	17.98	14.24	6	16578	743	110571972
Gingival oedema	17.95	14.24	4	16580	107	110572608
Myocardial infarction	17.57	14.24	66	16518	192017	110380698
Diabetes mellitus inadequate control	17.56	14.24	22	16562	29753	110542962
Toxic encephalopathy	17.45	14.24	16	16568	15198	110557517
Muscle spasms	17.28	14.24	85	16499	278072	110294643
Gamma-glutamyltransferase increased	17.12	14.24	32	16552	61277	110511438
Bile duct stone	16.97	14.24	11	16573	6278	110566437
Intentional product use issue	16.91	14.24	8	16576	247898	110324817
Cardiac failure chronic	16.78	14.24	15	16569	13796	110558919
Bronchitis chronic	16.77	14.24	10	16574	4930	110567785
Renal disorder	16.62	14.24	28	16556	49451	110523264
Angina unstable	16.40	14.24	16	16568	16416	110556299
Gastric dysplasia	16.32	14.24	3	16581	29	110572686
Cardio-respiratory arrest	16.19	14.24	46	16538	115790	110456925
Tinnitus	16.16	14.24	31	16553	60509	110512206
Pemphigus	16.12	14.24	6	16578	214564	110358151
Disseminated intravascular coagulation	16.10	14.24	25	16559	41261	110531454
Glucose-6-phosphate dehydrogenase deficiency	16.07	14.24	5	16579	496	110572219
Rheumatoid arthritis	15.84	14.24	13	16571	299600	110273115
Folliculitis	15.78	14.24	3	16581	167650	110405065
Blood urea increased	15.74	14.24	29	16555	54928	110517787
Psoriatic arthropathy	15.65	14.24	5	16579	196756	110375959
Generalised oedema	15.48	14.24	21	16563	30683	110542032
Thalamus haemorrhage	15.47	14.24	7	16577	1957	110570758
Irritable bowel syndrome	15.32	14.24	3	16581	164212	110408503
Bladder cancer	15.30	14.24	17	16567	20275	110552440
Infusion related reaction	15.17	14.24	21	16563	381141	110191574
Injury	15.02	14.24	4	16580	177261	110395454
Radiation pneumonitis	14.93	14.24	9	16575	4527	110568188
Vessel puncture site haematoma	14.69	14.24	4	16580	248	110572467
Head discomfort	14.46	14.24	16	16568	18984	110553731
Hypothyroidism	14.41	14.24	33	16551	72866	110499849
Diabetic nephropathy	14.30	14.24	8	16576	3500	110569215

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AA08	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors
ATC	C10BA13	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
ATC	C10BA14	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, COMBINATIONS Combinations of various lipid modifying agents
FDA MoA	N0000000121	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D000924	Anticholesteremic Agents
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019161	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D057847	Lipid Regulating Agents
FDA EPC	N0000175589	HMG-CoA Reductase Inhibitor
CHEBI has role	CHEBI:22586	antioxidant
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35610	antineoplastic agent

Related Drugs by ATC class:

C10AA HMG CoA reductase inhibitors 7 drugs

atorvastatin cerivastatin fluvastatin lovastatin pravastatin rosuvastatin simvastatin

C10BA Combinations of various lipid modifying agents 9 drugs

atorvastatin bempedoic acid ezetimibe fenofibrate lovastatin nicotinic acid pravastatin rosuvastatin simvastatin

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Mixed hyperlipidemia	indication	267434003
Familial hypercholesterolemia	indication	398036000	DOID:13810
Dehydration	contraindication	34095006
Hypothyroidism	contraindication	40930008	DOID:1459
Low blood pressure	contraindication	45007003
Acute infectious disease	contraindication	63171007
Disorder of muscle	contraindication	129565002	DOID:423
Liver function tests abnormal	contraindication	166603001
Impaired renal function disorder	contraindication	197663003
Hemorrhagic cerebral infarction	contraindication	230706003
Disease of liver	contraindication	235856003	DOID:409
Sepsis syndrome	contraindication	238150007
Rhabdomyolysis	contraindication	240131006
Pregnancy, function	contraindication	289908002
Surgical procedure	contraindication	387713003
Breastfeeding (mother)	contraindication	413712001
Traumatic injury	contraindication	417746004
Uncontrolled Epilepsy	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.05	acidic
pKa2	13.01	acidic
pKa3	13.99	acidic
pKa4	5.11	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme	P04035	HMDH_HUMAN	INHIBITOR	IC50	8.17	WOMBAT-PK	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Kd	4.88	CHEMBL
Nuclear receptor subfamily 4 group A member 2	Nuclear other	P43354	NR4A2_HUMAN		EC50	6.92	CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_RAT		IC50	4.98	CHEMBL

External reference:

ID	Source
4029463	VUID
N0000180308	NUI
D01862	KEGG_DRUG
147526-32-7	SECONDARY_CAS_RN
4029463	VANDF
4037418	VANDF
C1101838	UMLSCUI
CHEBI:32020	CHEBI
PV9	PDB_CHEM_ID
CHEMBL1201753	ChEMBL_ID
CHEMBL1237061	ChEMBL_ID
DB08860	DRUGBANK_ID
C108475	MESH_SUPPLEMENTAL_RECORD_UI
5282452	PUBCHEM_CID
3035	IUPHAR_LIGAND_ID
7730	INN_ID
M5681Q5F9P	UNII
861612	RXNORM
173089	MMSL
27200	MMSL
33902	MMSL
372947	MMSL
d07637	MMSL
013206	NDDF
013429	NDDF
443585001	SNOMEDCT_US
443586000	SNOMEDCT_US
700402009	SNOMEDCT_US
M5681Q5F9P	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pitavastatin Calcium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5055	TABLET, FILM COATED	1 mg	ORAL	ANDA	26 sections
Pitavastatin Calcium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5056	TABLET, FILM COATED	2 mg	ORAL	ANDA	26 sections
Pitavastatin Calcium	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5057	TABLET, FILM COATED	4 mg	ORAL	ANDA	26 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0480-3631	TABLET, FILM COATED	1.05 mg	ORAL	ANDA	17 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0480-3632	TABLET, FILM COATED	2.09 mg	ORAL	ANDA	17 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0480-3633	TABLET, FILM COATED	4.18 mg	ORAL	ANDA	17 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6048	TABLET	1 mg	ORAL	ANDA	30 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6049	TABLET	2 mg	ORAL	ANDA	30 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-6050	TABLET	4 mg	ORAL	ANDA	30 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-201	TABLET, FILM COATED	2 mg	ORAL	NDA	26 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-202	TABLET, FILM COATED	4 mg	ORAL	NDA	26 sections
pitavastatin calcium	HUMAN PRESCRIPTION DRUG LABEL	1	31722-875	TABLET, FILM COATED	1.05 mg	ORAL	ANDA	26 sections
pitavastatin calcium	HUMAN PRESCRIPTION DRUG LABEL	1	31722-876	TABLET, FILM COATED	2.09 mg	ORAL	ANDA	26 sections
pitavastatin calcium	HUMAN PRESCRIPTION DRUG LABEL	1	31722-877	TABLET, FILM COATED	4.18 mg	ORAL	ANDA	26 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42291-905	TABLET, FILM COATED	1.05 mg	ORAL	ANDA	18 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42291-906	TABLET, FILM COATED	2.09 mg	ORAL	ANDA	18 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	42291-907	TABLET, FILM COATED	4.18 mg	ORAL	ANDA	18 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	51407-956	TABLET	1 mg	ORAL	ANDA	30 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	51407-957	TABLET	2 mg	ORAL	ANDA	30 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	51407-958	TABLET	4 mg	ORAL	ANDA	30 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	65162-029	TABLET, FILM COATED	1 mg	ORAL	ANDA	23 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	65162-030	TABLET, FILM COATED	2 mg	ORAL	ANDA	23 sections
Pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	65162-031	TABLET, FILM COATED	4 mg	ORAL	ANDA	23 sections
Pitavastatin	Human Prescription Drug Label	1	65862-812	TABLET, FILM COATED	1 mg	ORAL	ANDA	25 sections
Pitavastatin	Human Prescription Drug Label	1	65862-813	TABLET, FILM COATED	2 mg	ORAL	ANDA	25 sections
Pitavastatin	Human Prescription Drug Label	1	65862-814	TABLET, FILM COATED	4 mg	ORAL	ANDA	25 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-104	TABLET, FILM COATED	1.05 mg	ORAL	NDA	30 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-204	TABLET, FILM COATED	2.09 mg	ORAL	NDA	30 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-404	TABLET, FILM COATED	4.18 mg	ORAL	NDA	30 sections
pitavastatin	HUMAN PRESCRIPTION DRUG LABEL	1	68180-735	TABLET, FILM COATED	1 mg	ORAL	ANDA	24 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

pitavastatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: